Literature DB >> 22737599

SCHEMA-designed variants of human Arginase I and II reveal sequence elements important to stability and catalysis.

Philip A Romero1, Everett Stone, Candice Lamb, Lynne Chantranupong, Andreas Krause, Aleksandr E Miklos, Randall A Hughes, Blake Fechtel, Andrew D Ellington, Frances H Arnold, George Georgiou.   

Abstract

Arginases catalyze the divalent cation-dependent hydrolysis of L-arginine to urea and L-ornithine. There is significant interest in using arginase as a therapeutic antineogenic agent against L-arginine auxotrophic tumors and in enzyme replacement therapy for treating hyperargininemia. Both therapeutic applications require enzymes with sufficient stability under physiological conditions. To explore sequence elements that contribute to arginase stability we used SCHEMA-guided recombination to design a library of chimeric enzymes composed of sequence fragments from the two human isozymes Arginase I and II. We then developed a novel active learning algorithm that selects sequences from this library that are both highly informative and functional. Using high-throughput gene synthesis and our two-step active learning algorithm, we were able to rapidly create a small but highly informative set of seven enzymatically active chimeras that had an average variant distance of 40 mutations from the closest parent arginase. Within this set of sequences, linear regression was used to identify the sequence elements that contribute to the long-term stability of human arginase under physiological conditions. This approach revealed a striking correlation between the isoelectric point and the long-term stability of the enzyme to deactivation under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22737599      PMCID: PMC3378063          DOI: 10.1021/sb300014t

Source DB:  PubMed          Journal:  ACS Synth Biol        ISSN: 2161-5063            Impact factor:   5.110


  41 in total

1.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

2.  Supercharging proteins can impart unusual resilience.

Authors:  Michael S Lawrence; Kevin J Phillips; David R Liu
Journal:  J Am Chem Soc       Date:  2007-08-01       Impact factor: 15.419

3.  A diverse family of thermostable cytochrome P450s created by recombination of stabilizing fragments.

Authors:  Yougen Li; D Allan Drummond; Andrew M Sawayama; Christopher D Snow; Jesse D Bloom; Frances H Arnold
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

4.  The Biology Workbench--a seamless database and analysis environment for the biologist.

Authors:  S Subramaniam
Journal:  Proteins       Date:  1998-07-01

Review 5.  Hyperargininemia due to liver arginase deficiency.

Authors:  Eric A Crombez; Stephen D Cederbaum
Journal:  Mol Genet Metab       Date:  2004-12-19       Impact factor: 4.797

6.  Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.

Authors:  Everett M Stone; Evan S Glazer; Lynne Chantranupong; Paul Cherukuri; Robert M Breece; David L Tierney; Steven A Curley; Brent L Iverson; George Georgiou
Journal:  ACS Chem Biol       Date:  2010-03-19       Impact factor: 5.100

7.  Probing the specificity determinants of amino acid recognition by arginase.

Authors:  Ekaterina Y Shishova; Luigi Di Costanzo; Francis A Emig; David E Ash; David W Christianson
Journal:  Biochemistry       Date:  2009-01-13       Impact factor: 3.162

8.  Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning.

Authors:  Samuel A Danziger; Roberta Baronio; Lydia Ho; Linda Hall; Kirsty Salmon; G Wesley Hatfield; Peter Kaiser; Richard H Lathrop
Journal:  PLoS Comput Biol       Date:  2008-09-04       Impact factor: 4.475

9.  A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach.

Authors:  Peng Wang; John Sidney; Courtney Dow; Bianca Mothé; Alessandro Sette; Bjoern Peters
Journal:  PLoS Comput Biol       Date:  2008-04-04       Impact factor: 4.475

10.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.

Authors:  Morten Nielsen; Claus Lundegaard; Ole Lund
Journal:  BMC Bioinformatics       Date:  2007-07-04       Impact factor: 3.169

View more
  14 in total

1.  Arginase as a new concern in blood transfusion.

Authors:  Faustino Mollinedo; Miguel Angel Palomero-Rodríguez; Pilar Sánchez-Conde; Rósula García-Navas; Yolanda Laporta-Báez; Jesús de Vicente-Sánchez; Luis Suarez-Gonzalo
Journal:  Blood Transfus       Date:  2013-05-29       Impact factor: 3.443

2.  Structure-guided SCHEMA recombination generates diverse chimeric channelrhodopsins.

Authors:  Claire N Bedbrook; Austin J Rice; Kevin K Yang; Xiaozhe Ding; Siyuan Chen; Emily M LeProust; Viviana Gradinaru; Frances H Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-10       Impact factor: 11.205

3.  Chimeragenesis of distantly-related proteins by noncontiguous recombination.

Authors:  Matthew A Smith; Philip A Romero; Timothy Wu; Eric M Brustad; Frances H Arnold
Journal:  Protein Sci       Date:  2012-12-29       Impact factor: 6.725

4.  Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Authors:  Juan Carlos Almagro; Gary L Gilliland; Felix Breden; Jamie K Scott; Devin Sok; Matthias Pauthner; Janice M Reichert; Gustavo Helguera; Raiees Andrabi; Robert Mabry; Mathieu Bléry; James E Voss; Juha Laurén; Lubna Abuqayyas; Stefan Barghorn; Eshel Ben-Jacob; James E Crowe; James S Huston; Stephen Albert Johnston; Eric Krauland; Fridtjof Lund-Johansen; Wayne A Marasco; Paul W H I Parren; Kai Y Xu
Journal:  MAbs       Date:  2014-03-03       Impact factor: 5.857

5.  Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.

Authors:  Terry Jo V Bichell; Michal Wegrzynowicz; K Grace Tipps; Emma M Bradley; Michael A Uhouse; Miles Bryan; Kyle Horning; Nicole Fisher; Karrie Dudek; Timothy Halbesma; Preethi Umashanker; Andrew D Stubbs; Hunter K Holt; Gunnar F Kwakye; Andrew M Tidball; Roger J Colbran; Michael Aschner; M Diana Neely; Alba Di Pardo; Vittorio Maglione; Alexander Osmand; Aaron B Bowman
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-16       Impact factor: 5.187

6.  Learning epistatic interactions from sequence-activity data to predict enantioselectivity.

Authors:  Julian Zaugg; Yosephine Gumulya; Alpeshkumar K Malde; Mikael Bodén
Journal:  J Comput Aided Mol Des       Date:  2017-12-12       Impact factor: 3.686

7.  SCHEMA computational design of virus capsid chimeras: calibrating how genome packaging, protection, and transduction correlate with calculated structural disruption.

Authors:  Michelle L Ho; Benjamin A Adler; Michael L Torre; Jonathan J Silberg; Junghae Suh
Journal:  ACS Synth Biol       Date:  2013-08-22       Impact factor: 5.110

8.  In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ.

Authors:  David S Ojala; Sabrina Sun; Jorge L Santiago-Ortiz; Mikhail G Shapiro; Philip A Romero; David V Schaffer
Journal:  Mol Ther       Date:  2017-09-08       Impact factor: 11.454

9.  Random field model reveals structure of the protein recombinational landscape.

Authors:  Philip A Romero; Frances H Arnold
Journal:  PLoS Comput Biol       Date:  2012-10-04       Impact factor: 4.475

Review 10.  Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.

Authors:  Andrew Currin; Neil Swainston; Philip J Day; Douglas B Kell
Journal:  Chem Soc Rev       Date:  2015-03-07       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.